Literature DB >> 22958029

Inhibitors of gastric acid secretion drugs increase neonatal morbidity and mortality.

Gianluca Terrin1, Roberto Berni Canani, Annalisa Passariello, Stefano Caoci, Mario De Curtis.   

Abstract

AIMS: To analyze all evidence on the possible increase in morbidity and mortality determined by the use of inhibitors of gastric acid secretion (IGAS) drugs.
MATERIALS AND METHODS: We review all evidence exploring the adverse events associated with IGAS use in neonates.
RESULTS: Despite being prescribed in an off-label manner because of the perceived safety and potential benefit demonstrated for older populations, IGAS are being increasingly used in the neonatal period with much evidence derived from adults and children. Few data are available for neonates and indicate an association between IGAS use with infections and necrotizing enterocolitis (NEC), and with an increased mortality. Delayed gastric emptying, increased gastric mucus viscosity, modification in microbiota, and impairment of neutrophils functions are possible mechanisms of adverse events associated with IGAS use.
CONCLUSIONS: A careful prescription of IGAS is crucial in order to reduce iatrogenic damage in neonates.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22958029     DOI: 10.3109/14767058.2012.714975

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  2 in total

1.  Use of ranitidine is associated with infections in newborns hospitalized in a neonatal intensive care unit: a cohort study.

Authors:  Ruth N S Santana; Victor S Santos; Ruy F Ribeiro-Júnior; Marina S Freire; Maria A S Menezes; Rosana Cipolotti; Ricardo Q Gurgel
Journal:  BMC Infect Dis       Date:  2017-05-30       Impact factor: 3.090

2.  Association between histamine-2 receptor antagonists and adverse outcomes in neonates: A systematic review and meta-analysis.

Authors:  Victor S Santos; Marina S Freire; Ruth N S Santana; Paulo R S Martins-Filho; Luis E Cuevas; Ricardo Q Gurgel
Journal:  PLoS One       Date:  2019-04-04       Impact factor: 3.240

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.